Inclusion Criteria:

          1. Written informed consent signed by the patient, or parents or legal representative and
             assent of the minor child.

          2. Age: 6 months to < 21 years of age at time of study entry

          3. Histologically confirmed low-grade glioma in non-NF1 patients (no further biopsy is
             needed at study entry). For patients with NF1, no biopsy is required to confirm the
             radiological diagnosis of the low grade glioma.

          4. Relapse or refractory tumor after at least one first-line therapy, not taking into
             account surgery only.

          5. Evaluable Disease on morphologic MRI

          6. Karnofsky performance status score >=70% for patients >12 years of age, or Lansky
             score >=70% for patients <=12 years of age, including patients with motor paresis due
             to disease.

          7. Life expectancy >= 3 months.

          8. Adequate organ function:

               -  Adequate hematopoietic function: neutrophils ³1.0 x 109/L, platelets ³100 x
                  109/L; hemoglobin ³8 g/dL

               -  Adequate renal function: serum creatinine < 1.5 x ULN for age 0 - 1 year: <= 40
                  µmol/L

                  1 - 15 years: <= 65 µmol/L 15 - 20 years: <= 110 µmol/L In case serum creatinine
                  >1.5 ULN according to age, creatinine clearance has to be >70 mL/min/1.73 m2 or
                  glomerular filtration rate measurement >70% of the expected value

               -  Adequate electrolytes levels: potassium, magnesium, phosphor, total calcium Lower
                  Limit of Normal (LLN)

               -  Adequate hepatic function: total bilirubin <=1.5 x ULN; AST and ALT <=2.5 x ULN.

               -  Absence of peripheral neuropathy >= grade 2 (Common Toxicity Criteria Adverse
                  Event, NCI CTCAE v4.0)

               -  Adequate cardiac function:

             Shortening Fraction (SF) >= 28% (35% for children <3 years) and Left Ventricular
             Ejection Fraction (LVEF) >= 50% at baseline, as determined by echocardiography

             Absence of QTc prolongation (QTc > 450 msec on baseline ECG, using the QTcF formula)
             or other clinically significant ventricular or atrial arrhythmia

          9. Wash-out period of at least

               -  3 weeks in case of preliminary chemotherapy,

               -  6 weeks in case of nitrosourea-containing chemotherapy,

               -  2 weeks in the case of treatment with vincristine only

               -  6 weeks in case of radiation therapy

         10. Possibility of receiving the therapeutic schedule as indicated in the protocol

         11. Patients with reproductive potential must use effective contraception during their
             treatment and for up to 90 days after the last dose. Females with reproductive
             potential must have a negative pregnancy test <= 7 days before starting Nilotinib
             and/or Vinblastine.

         12. Patients already treated with one of the two drugs can be enrolled in the trial
             provided that rechallenging them with the same drug could be considered acceptable

        Exclusion Criteria:

          1. Concomitant anti-tumor treatment

          2. Not recovered to <Grade 2 from the acute toxic effects of all prior chemotherapy,
             immunotherapy or radiotherapy

          3. Known intolerance or hypersensitivity to Vinblastine

          4. Existence of another severe systemic disease

          5. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or
             antifungal medicines,

          6. Any concurrent illness which in the opinion of the investigator may interfere with the
             treatment and evaluation of the patient

          7. Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of nilotinib.

          8. Simultaneous treatment with strong cytochromes P450 CYP3A4 inhibitors (e.g.
             antiepileptic drugs, see complete list in the Appendix 5).

          9. Simultaneous treatment with antiarrythmic drugs and other drugs known to prolong QT
             interval (cloroquine, halofantrine, clarithromycin, haloperidol, methadone,
             moxifloxacin, bepridil, cisapride and pimozide). A list of QT prolonging compounds can
             be found at http://www.azcert.org/medical-pros/druglists/drug-lists.cfm (Appendix 6)

         10. Impaired cardiac function including any one of the following:

               -  Clinically significant resting brachycardia (<50 beats per minute).

               -  QTc > 450 msec on baseline ECG. If QTc >450 msec and electrolytes are not within
                  normal ranges, electrolytes should be corrected and then the patient re-screened
                  for QTc.

               -  Other clinically significant uncontrolled heart disease (e.g. unstable angina,
                  congestive heart failure or uncontrolled hypertension).

               -  History of or presence of clinically significant ventricular or atrial
                  tachyarrhythmias (including congenital long QT syndrome or a known family history
                  of congenital long QT syndrome)